Author:
Dudda Angela,Kuerzel Gert Ulrich
Publisher
Springer International Publishing
Reference62 articles.
1. Abecassis PY (2003) 8th European ISSX Meeting, short course: P450 inhibition/P450 inactivation April 27–May 1, 2003, Dijon, France
2. Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, Walker DK (2001) Potential role of p-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 31(8/9):665–676
3. Backes WL, Kelley RW (2003) Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther 98(2):221–233. https://doi.org/10.1016/S0163-7258(03)00031-7
4. Benoussan C, Delaforge M, Mansuy D (1995) Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 49(5):591–602
5. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT (1992) The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Pharmacol 33:521–523